Intraday Q1 preview 09 Apr 2026: 5CV.DE stock CureVac N.V. (XETRA): Key catalysts

5CV.DE stock trades at €3.91 as traders position ahead of CureVac N.V.’s Q1 report due 09 Apr 2026 at 09:00 CEST. The company reports tomorrow, and short-term moves may hinge on trial updates and contract progress. We highlight valuation, key metrics, and analyst-driven scenarios for intraday trading and earnings reaction.

Earnings context for 5CV.DE stock

CureVac N.V. (5CV.DE) reports Q1 results on 09 Apr 2026 at 09:00 CEST. Expect revenue, cash-flow commentary, and program milestones for mRNA candidates to dominate headlines.

Management guidance and any change to development timelines will drive intraday volatility. The market will read clinical progress and partner updates as direct earnings catalysts.

Price action and valuation of 5CV.DE stock

The stock is at €3.91, up 0.72% intraday, with volume 125,272 versus average 168,173. Day range is €3.86–€3.96, year high €4.90, year low €2.00.

CureVac trades at P/E 6.85 and P/B 1.01, well below the Healthcare sector average P/E 28.97, implying market skepticism despite positive earnings yield.

Financials and key metrics for 5CV.DE stock

Latest data shows EPS €0.57, market cap €879.52m, and cash per share €1.86. Current ratio is 3.70, and ROE is 18.40%.

Free cash flow remains negative. Enterprise value over EBITDA is 2.75, reflecting low valuation vs peers but higher operational risk given R&D intensity.

Meyka AI grade and forecast for 5CV.DE stock

Meyka AI rates 5CV.DE with a score out of 100. Meyka AI assigns a score of 71.43 out of 100 (B+) and suggests BUY. This grade factors S&P 500 and sector comparisons, financial growth, metrics, and analyst consensus.

Meyka AI’s forecast model projects a quarterly target of €4.74, implying an upside of 21.36% versus the current price €3.91. Forecasts are model-based projections and not guarantees.

Risks and catalysts for 5CV.DE stock

Catalysts include clinical readouts, partner deals, and clearer revenue guidance. Positive trial news could lift sentiment quickly.

Risks are missed milestones, cash-flow pressure, and sector rotation away from biotech. Low average volume increases short-term volatility around the earnings release.

Trading setup and technicals for 5CV.DE stock

Short-term traders should watch 50-day average €4.29 and 200-day average €4.17 as resistance. Support sits near €3.86 intraday and €2.00 yearly low.

Use tight risk controls since liquidity is light and earnings can spark >10% moves during intraday sessions.

Final Thoughts

Key takeaways for 5CV.DE stock ahead of Q1: CureVac trades at €3.91 with a market cap of €879.52m and a low P/E of 6.85, offering a value angle versus the Healthcare sector. Meyka AI’s model projects a near-term quarterly target of €4.74, implying +21.36% upside versus today. Our scenario targets show a conservative floor at €3.00 (down -23.22%), a base case €4.50 (up +15.21%), and a bull case €5.50 (up +40.81%). Remember this stock remains R&D-heavy with negative free cash flow, and earnings on 09 Apr 2026 at 09:00 CEST can trigger wide moves. Use the Meyka AI grade and model forecasts as input, not as guarantees, and size positions to limit downside risk

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.